Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

In October 2026, Viatris Inc. entered into a definitive agreement to acquire Pacira BioSciences, Inc. for approximately USD 1.65 billion in equity value. Announced on October 8, the transaction represents a significant step in Viatris’s strategy to expand its position in non-opioid pain management. The acquisition will add two established, patent-protected medicines, EXPAREL and ZILRETTA, to Viatris ' portfolio while expanding its commercial, medical affairs, market access, and research and development capabilities in the United States.

Under the agreement, Viatris will acquire Pacira’s outstanding common shares for $36.50per share in cash. The transaction is expected to close by the end of 2026, subject to applicable conditions. Viatris anticipates that the acquisition will contribute immediately to its financial guidance metrics and complement its existing pain management development opportunities. The agreement reflects the company’s focus on acquiring established medicine that can support sustainable revenue growth and strengthen its presence in specialized therapeutic areas.

Expanding Viatris Innovative Medicines Strategy

The acquisition is an important development in Viatris efforts to build a stronger innovative medicines business. The company has been working to expand beyond its established pharmaceutical portfolio by investing in differentiated treatments and products with opportunities for sustained commercial performance.

Pacira brings two marketed medicines used in pain management. EXPAREL is a liposomal formulation of bupivacaine indicated for postsurgical pain management, while ZILRETTA is an extended-release injectable formulation of triamcinolone acetonide used to manage osteoarthritis knee pain.

These products offer Viatris an opportunity to strengthen its presence in non-opioid pain treatment through medicines that are already commercially established in the United States. Instead of relying exclusively on the development of new treatments, the acquisition provides access to existing products with established clinical use and commercial infrastructure.

According to the company's announcement, Pacira generated approximately $746million in total revenue and USD 177million in adjusted EBITDA during the 12-month period ended June 30, 2026. These financial results highlight the commercial scale of the business Viatris intends to acquire.

Viatris plans to use its intellectual property expertise, commercial infrastructure, and experience managing product lifecycles to maximize the long-term value of Pacira’s portfolio.
Focus on Non-Opioid Pain Management

The agreement comes as healthcare providers continue to seek additional options for managing acute and chronic pain. Pain management remains an important area of healthcare, particularly for patients recovering from surgery and those living with conditions such as osteoarthritis.

EXPAREL is designed to provide extended-release local pain relief following surgery. Its liposomal formulation supports the gradual release of bupivacaine, a local anesthetic. ZILRETTA uses extended-release technology to deliver triamcinolone acetonide for osteoarthritis knee pain.

The medicines address different clinical needs, giving Viatris access to treatments used in both postsurgical pain management and joint-related pain. Their addition is expected to complement the company’s broader strategy of developing and commercializing non-opioid treatment options.

Non-opioid therapies are an important part of efforts to broaden pain management choices. However, treatment decisions depend on individual patient needs, clinical evidence, product indication, and healthcare professional judgement. The acquisition does not itself establish new clinical benefits or expand the approved use of either medicine.

International Expansion Opportunities

iatris expands the reach of EXPAREL and ZILRETTA across selected markets by leveraging its international infrastructure. Its global presence could provide opportunities to extend the commercial availability of these medicines where regulatory approvals and local market conditions permit.

International expansion could help increase the long-term value of Pacira’s products by connecting them with additional healthcare markets. However, opportunities will depend on regulatory requirements, market access arrangements, reimbursement conditions, and demand from healthcare providers.

The acquisition also strengthens Viatris capabilities in the U.S. market, including commercial operations, medical affairs, market access, and global research and development. These capabilities could support future product development and commercialization activities across selected specialty-driven therapeutic areas.

For Pacira, joining Viatris would provide access to a broader global healthcare platform. For Viatris, the transaction offers an opportunity to combine established pain medicines with existing commercial resources and international operations.

Complementing the Fast-Acting Meloxicam Opportunity

Another important element of the agreement is the potential relationship with Viatris’s fast-acting meloxicam opportunity. The company is pursuing this treatment for moderate-to-severe acute pain, with the new drug application accepted by the U.S. Food and Drug Administration in May 2026.

The planned acquisition could create strategic alignment between Pacira’s established non-opioid pain medicines and Viatris’s own development and commercialization efforts. Together, these assets could strengthen the company’s position across selected pain management applications.

The potential benefits extend beyond adding products to the portfolio. Viatris could use its combined expertise in research, medical affairs, market access, and commercialization to support a more integrated approach to pain management.

Nevertheless, the commercial outlook for fast-acting meloxicam remains dependent on regulatory review and other factors. The acquisition and the pending medicine represent complementary opportunities rather than a guarantee of future market performance.

Financial Impact and Transaction Outlook

Viatris has stated that the acquisition is consistent with its disciplined capital allocation strategy and is expected to preserve financial flexibility. The company anticipates that the transaction will be immediately accretive to its financial guidance metrics.

The $1.65 billion equity valuation reflects the value of Pacira’s established medicines, commercial operations, and development capabilities. For Viatris, acquiring an operating business with marketed products offers a route to expanding its innovative medicines portfolio while pursuing opportunities for revenue and earnings growth.

The transaction is expected to close by the end of 2026, subject to the applicable closing conditions. Until completion, Pacira and Viatris remain separate companies, and the proposed acquisition should not be interpreted as a completed transaction.

Successful integration will be important for realizing the expected benefits. Product commercialization, regulatory compliance, intellectual property management, and international expansion will all influence the long-term performance of the combined portfolio.

Future Opportunities for the Pharmaceutical Industry

The proposed acquisition highlights the growing role of strategic transactions in pharmaceutical portfolio development. Companies are increasingly evaluating established specialty medicines, differentiated formulations, and products addressing significant treatment needs as ways to strengthen their market positions.

For the pain management sector, the agreement underscores continued interest in non-opioid treatment options. Investments in established medicines and complementary development programs could support broader treatment portfolios, although their impact will depend on clinical evidence, competition, access, and regulatory outcomes.

The transaction may also illustrate how global pharmaceutical companies can use commercial infrastructure to expand the reach of acquired medicines. By combining established products with international operations and research capabilities, companies can pursue additional markets while seeking to manage development and commercialization costs.

Conclusion

Viatris’s agreement to acquire Pacira BioScience for $1.65billion marks a significant step in its strategy to expand its innovative medicines business and strengthen its position in non-opioid pain management. The proposed acquisition adds EXPAREL and ZILRTTA, two established medicines for postsurgical pain and osteoarthritic knee pain, while providing opportunities for international expansion and stronger commercial capabilities.

The transaction is also expected to complement Viatris’ fast-acting meloxicam opportunity and support its broader growth strategy. With completion anticipated by the end of 2026, the deal could strengthen Viatris’ presence in specialized pain therapies while highlighting the pharmaceutical industry’s continued focus on differentiated medicines and strategic portfolio expansion.